Human papillomavirus vaccines and vaccine implementation (Q37346095)

19 August 2017

1 reference

title

Human papillomavirus vaccines and vaccine implementation (English)

1 reference

Francesc Xavier Bosch José

19 August 2017

1 reference

3

Xavier Castellsagué

0 references

Silvia de Sanjosé

series ordinal

1

object named as

Silvia de Sanjosé

0 references

series ordinal

4

object named as

F Xavier Bosch

2 references

ORCID Public Data File 2021

19 August 2017

2

Laia Alemany

1 reference

19 August 2017

1 November 2008

1 reference

19 August 2017

1 reference

19 August 2017

4

1 reference

19 August 2017

6

1 reference

19 August 2017

595-604

1 reference

Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group

19 August 2017

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Human papillomavirus is a necessary cause of invasive cervical cancer worldwide

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Human papillomavirus and cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Genome variation of human papillomavirus types: phylogenetic and medical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Epidemiologic classification of human papillomavirus types associated with cervical cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

The carcinogenicity of human papillomavirus types reflects viral evolution.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Against which human papillomavirus types shall we vaccinate and screen? The international perspective

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Chapter 2: The burden of HPV-related cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Chapter 10: New dimensions in cervical cancer screening

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Overview of human papillomavirus-based and other novel options for cervical cancer screening in developed and developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

HPV and cervical cancer: screening or vaccination?

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Chapter 15: HPV vaccine use in the developing world

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Chapter 30: HPV vaccines and screening in the prevention of cervical cancer; conclusions from a 2006 workshop of international experts

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Latin America. Price is the main barrier to wider use of papillomavirus vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Chapter 26: Innovative financing mechanisms to accelerate the introduction of HPV vaccines in developing countries

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Health and economic outcomes of HPV 16,18 vaccination in 72 GAVI-eligible countries

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Chapter 24: Psychosocial aspects of vaccine acceptability.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

Generic HIV drugs--enlightened policy for global health.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

The causal link between human papillomavirus and invasive cervical cancer: a population-based case-control study in Colombia and Spain

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F17455057.4.6.595

21 January 2018

Identifiers

DOI

10.2217/17455057.4.6.595

1 reference

19 August 2017

1 reference

PubMed ID

19072462